Dare Bioscience, Inc. DARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-20.96
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.0M | -$13.4M | — | -$10.3M | $2.8M |
| 2024 | $9,784 | -$4.1M | — | $4.9M | -$6.0M |
| 2023 | $2.8M | -$30.2M | — | -$39.5M | -$5.0M |
| 2022 | $10.0M | -$30.9M | — | -$18.2M | $11.1M |
| 2021 | $0 | -$38.7M | — | -$28.8M | $38.8M |
| 2020 | — | -$27.4M | — | -$25.3M | -$1.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -20.96 (distress)
- Working capital / assets 0.104
- Retained earnings / assets -5.81
- EBIT / assets -0.417
- Equity / liabilities 0.096
Source: SEC EDGAR filings · CIK 0001401914 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.